Interferon News and Research

RSS

Boehringer Ingelheim announces new data from hepatitis C virus portfolio

Boehringer Ingelheim announced today that new data from its hepatitis C virus (HCV) portfolio will be presented in scientific sessions at The Liver Meeting 2011, the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 4 - November 8 in San Francisco, CA.

22 Oct 2011

Roche to acquire Anadys Pharmaceuticals

Anadys Pharmaceuticals, Inc. today announced that it has entered into a definitive merger agreement to be acquired by Roche.

18 Oct 2011

Molecular switch activates anti-viral innate immune response

When a thief breaks into a bank vault, sensors are activated and the alarm is raised. Cells have their own early-warning system for intruders, and scientists at the European Molecular Biology Laboratory (EMBL) in Grenoble, France, have discovered how a particular protein sounds that alarm when it detects invading viruses.

15 Oct 2011

ABI provides clinical update on company activities

Amarillo Biosciences, Inc. (ABI) today provided an update on company activities.

15 Oct 2011

Positive data from Anadys' setrobuvir Phase IIb combination study on genotype 1 HCV

Anadys Pharmaceuticals, Inc. today released interim antiviral response and safety data from an ongoing Phase IIb study of setrobuvir in combination with pegylated interferon and ribavirin (P/R) in genotype 1 hepatitis C patients.

14 Oct 2011

Incoming dean of Weill Cornell receives 2011 ICS Honorary Lifetime Membership

Dr. Laurie Glimcher, the incoming dean of Weill Cornell Medical College, has received the 2011 International Cytokine Society (ICS) Honorary Lifetime Membership, the Society's highest honor, for her pivotal contributions to cytokine research, particularly as it relates to immune response.

12 Oct 2011

Vitamin D plays an essential role in the body's fight against TB

Not just important for building strong bones, an international team of scientists has found that vitamin D also plays an essential role in the body's fight against infections such as tuberculosis.

12 Oct 2011

PROLOR receives U.S. patent allowance for CTP-modified interferons

PROLOR Biotech, Inc. today announced that it received a notice of allowance from the U.S. Patent and Trademark Office (PTO) for a patent application covering PROLOR's CTP-modified interferons.

12 Oct 2011

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

Vertex Pharmaceuticals Incorporated announced today that INCIVEK (telaprevir) tablets are now available in Canada for people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

11 Oct 2011

Positive results from Biotron's BIT225 Phase 2a trial on HCV

Australian drug development company Biotron Limited has released headline results from its landmark Phase 2a trial of its lead drug candidate, BIT225 in Hepatitis C virus (HCV) infected patients.

11 Oct 2011

Pharmasset adds two treatment arms to PSI-7977 ELECTRON trial on HCV

Pharmasset, Inc. announced today the addition of two treatment arms to the ELECTRON trial of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C.

10 Oct 2011

VGX International, Inovio partner to co-develop SynCon vaccines for hepatitis B and C infections

Inovio Pharmaceuticals, Inc., a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that it has entered into a product development collaboration agreement with its affiliate, VGX International Inc., to co-develop Inovio's SynCon therapeutic vaccines for hepatitis B and C infections.

10 Oct 2011

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Bristol-Myers Squibb Company announced today that 22 abstracts on the Company's research in liver disease have been accepted for presentation at The Liver Meeting 2011, the 62nd annual meeting of the American Association for the Study of Liver Diseases, in San Francisco, November 4 - 8.

1 Oct 2011

New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011

Merck, known as MSD outside of the United States and Canada, announced today that several new analyses from Phase III studies of VICTRELIS (boceprevir), the company's first-in-class, oral hepatitis C virus NS3/4A protease inhibitor will be presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.

1 Oct 2011

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Vertex Pharmaceuticals Incorporated today announced that abstracts from its hepatitis C program, including two late-breaking posters from studies of INCIVEK (telaprevir) tablets and VX-222, were accepted for presentation at The Liver Meeting, the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.

1 Oct 2011

Patients with chronic hepatitis C less likely to take medications over time

Patients being treated for chronic hepatitis C become less likely to take their medications over time, according to a new study from the Perelman School of Medicine at the University of Pennsylvania.

30 Sep 2011

AASLD publishes updated practice guidelines on hepatitis C

On Monday, September 26, 2011, the American Association for the Study of Liver Diseases published online at its journal Hepatology's website an update to its practice guidelines for hepatitis C – "An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases."

29 Sep 2011

Phase I clinical trials reveal MVA-B preventive vaccine's immune efficiency against HIV

Phase I clinical trials developed by Spanish Superior Scientific Research Council (CSIC) together with Gregorio Mara--n Hospital in Madrid and Cl-nic Hospital in Barcelona, reveals MVA-B preventive vaccine's immune efficiency against Human's immunodeficiency virus (HIV).

28 Sep 2011

New FDA-approved antiviral drugs offer treatment hope for hepatitis C

The Methodist Hospital in Houston is excited to share significant news for patients who need treatment for hepatitis C genotype 1, a viral infection that causes liver inflammation that can lead to diminished liver function or symptoms for liver failure.

21 Sep 2011

Inhibitex initiates INX-189 combination Phase 2 trial in HCV-infected genotype 2/3 patients

Inhibitex, Inc., announced today that it has recently commenced dosing in a 90-patient randomized, placebo controlled, treatment guided, Phase 2 clinical trial to evaluate the safety, tolerability and antiviral activity of INX-189 in combination with pegylated interferon and ribavirin in chronic HCV-infected genotype 2 and 3 treatment naïve patients.

19 Sep 2011